Xenon Pharmaceuticals (XENE) Interest & Investment Income (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Interest & Investment Income of $6.9 million for Q1 2026, down 14.55% year-over-year from $8.1 million in Q1 2025, and up 29.34% quarter-over-quarter from $5.3 million in Q4 2025.
Powered by 
Analysis
Xenon Pharmaceuticals (XENE) Interest & Investment Income (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Interest & Investment Income for 14 consecutive years, with $6.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 14.55% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $25.7 million (down 33.67% YoY), while the FY2025 annual figure was $26.8 million, down 36.04% from the prior year.
- Interest & Investment Income rose to $6.9 million in Q1 2026 per XENE's latest filing, from $5.3 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $11.4 million in Q1 2024 and bottomed at $368000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $6.6 million across 5 years, with a median of $6.9 million in 2026.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 5278.95% — and 2025, when it tumbled 43.32%.
- Xenon Pharmaceuticals' Interest & Investment Income stood at $4.5 million in 2022, then jumped by 94.73% to $8.7 million in 2023, then climbed by 8.41% to $9.4 million in 2024, then sank by 43.32% to $5.3 million in 2025, then advanced by 29.34% to $6.9 million in 2026.
- Business Quant data shows XENE's Interest & Investment Income at $6.9 million in Q1 2026, $5.3 million in Q4 2025, and $6.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Xenon Pharmaceuticals | 5.94 Bn | 5.94 Bn | - | 12.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.15 Mn |
| Mar 31, 2026 | 6.91 Mn |
| Dec 31, 2025 | 5.34 Mn |
| Sep 30, 2025 | 6.21 Mn |
| Jun 30, 2025 | 7.20 Mn |
| Mar 31, 2025 | 8.08 Mn |
| Dec 31, 2024 | 9.42 Mn |
| Sep 30, 2024 | 10.33 Mn |
| Jun 30, 2024 | 10.84 Mn |
| Mar 31, 2024 | 11.36 Mn |
| Dec 31, 2023 | 8.69 Mn |
| Sep 30, 2023 | 6.98 Mn |
| Jun 30, 2023 | 6.52 Mn |
| Mar 31, 2023 | 5.42 Mn |
| Dec 31, 2022 | 4.46 Mn |
| Sep 30, 2022 | 3.07 Mn |
| Jun 30, 2022 | 816,000.00 |
| Mar 31, 2022 | 368,000.00 |
| Dec 31, 2021 | 191,000.00 |
| Sep 30, 2021 | 57,000.00 |